Biohaven Pharmaceuticals, Inc.
Clinical trials sponsored by Biohaven Pharmaceuticals, Inc., explained in plain language.
-
New drug shows promise for rare movement disorder
Symptom relief CompletedThis study tested a daily pill called troriluzole in 141 adults with spinocerebellar ataxia, a rare genetic disease that affects balance and coordination. Participants took either the drug or a placebo for 8 weeks. The main goal was to see if troriluzole could improve symptoms li…
Phase: PHASE2, PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 26, 2026 12:09 UTC
-
Could a new drug help when OCD medications fall short?
Symptom relief CompletedThis study tested whether adding troriluzole to standard OCD medications helps reduce symptoms in adults whose current treatment isn't working well enough. Over 400 participants received either troriluzole or a placebo alongside their usual medication. The main goal was to see if…
Phase: PHASE2, PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 26, 2026 11:09 UTC
-
Could a new pill ease OCD symptoms when standard meds fall short?
Symptom relief CompletedThis study tested whether adding troriluzole to standard OCD medication helps reduce symptoms more than a placebo. It involved 456 adults with OCD who had not responded well enough to their current treatment. The main goal was to see if troriluzole lowered scores on a standard OC…
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 22, 2026 13:53 UTC